The fact that different surfaces of the p85α BH domain are involved in regulating PTEN and Rab5 (Figure 5; [105,113]) means that clinically, cancers which have deregulated Rab5 functions as a result of p85α mutations may require very different treatments as compared to those where PTEN is deregulated. This evidence concerns the gene PTEN and cancer.